Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 22;12(11):732. doi: 10.3390/toxins12110732

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effect of OTA expositions on GPx activity in the kidney cortex. (A) GPx activity of kidney samples in case of single oral dose (24 h) OTA treatment. The applied OTA doses did not change significantly the GPx activity. (B) GPx activity of kidney samples in case of repeated daily oral dose (72 h) OTA treatment. The highest applied OTA dose decreased significantly (p < 0.05) the GPx activity. (C) GPx activity of kidney samples in case of repeated daily oral dose (21 days) OTA treatment. The applied OTA dose did not change the GPx activity significantly. Abbreviations: MMS: methyl-methanesulfonate-treated group; OTA 1 and OTA 10: treatment with 1 and 10 mg/kg bw ochratoxin A in the single oral dose (24 h) and repeated daily oral dose (72 h); OTA 0.5: 0.5 mg/kg bw ochratoxin A treatment in the repeated daily oral dose (21 days) experiment. Mean ± S.D. Data were analyzed by one-way ANOVA and Tukey’s post hoc test.* p < 0.05 vs. vehicle.